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Abstract. In the paper are presented the results obtained from processing serum samples 
from pigs with circovirus infection and vaccinated pigs against Porcine Circovirus Type 2 
(PCV-2 infections). The test kit used was SERELISA® PCV-2 Ab Mono Blocking 
(Synbiotics Europe, Lyon, France). 
Seroconversion in infected pigs was 20.5% and it was associated with the presence of 
clinical signs and skin lesions. 
In vaccinated pigs with circovirus vaccine, seroconversion was 94.1% at 55 days 
postvaccination and it decreased slowly in time, reaching 77.7% at 85 days postvaccination.   
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INTRODUCTION 
 
Postweaning multisystemic wasting syndrome (PMWS) is a disease of pigs first 
recognised in North America in 1997. Subsequently the syndrome was reported in many 
countries of Europe, America and Asia (Darwich et al., 2004).  
Porcine circovirus-2 (PCV-2) infection is recognized as the necessary cause of PMWS, 
a recently described and emerging disease problem in swine operations throughout the world 
(Krakowka et al., 2003). 
It is clinically characterized by progressive weight loss, dispneea, tachypnea and less 
frequent diarrhea, pallor and icterus in pigs (Kiupel et al., 2005). 
Porcine dermatitis and nephropathy syndrome (PDNS) is an emerging disease in 
growing nursery and fattening pigs that is being detected increasingly often in pig-producing 
countries throughout the world (Wellenberg et al., 2003). 
In the acute phase of the disease, PDNS affected pigs are clinically characterised by 
multifocal skin lesions, subcutaneous oedema, poor physical condition, progressive weight 
loss, dyspnea or tachypnea, and pallor (Wellenberg et al., 2004). 
  
MATERIALS AND METHODS 
 
Investigations were conducted during June-October 2010 on pigs sera originating from 
two Romanian farms (Farm A and B), where there had been reported the following symptoms: 
progressive weight loss, dispneea, tachypnea and less frequent diarrhea, pallor and icterus in 
weaned pigs. In fattening pigs there had been reported multifocal skin lesions, subcutaneous 
oedema, poor physical condition, progressive weight loss, dyspnea or tachypnea and pallor. 
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From farm A, suspected with circovirus infection, there were collected 39 blood samples 
from fattening pigs aged 2-3 months, which hadn’t been vaccinated against circovirus 
infection. 
From farm B there were collected 53 blood samples from vaccinated pigs at 21 days old 
with IngelvacCircoFlex vaccine (Boehringer Ingelheim). 
There were collected 17 blood samples at 55 days postvaccination, 18 blood samples at 
70 days postvaccination and 18 blood samples at 85 days postvaccination. 
Blood samples were processed in order to express sera and then they were stored in the 
freezer in order to be tested at the same parameters. 
Sera were processed using the SERELISA® PCV2 Ab Mono Blocking (Synbiotics 
Europe, Lyon, France) test kit according to the manufacturer’s instructions, kit that has also 
been used in previous studies (Lim et al., 2011). 
Samples were processed within the „Bacterial Infectious Diseases Research Laboratory” 
from Faculty of Veterinary Medicine Timisoara. 
 
RESULTS AND DISCUSSIONS 
 
Results obtained by using immunoenzymatic test were processed with the Quantitative 
Method calculations PCV-2 (Excel Spreadsheet) program. Synthesis is presented in table 1. 
 
Tab. 1 
The results synoptic regarding anti PCV-2 antibodies 
 
Examined farm Examined 
samples  
(No.) 
Negative 
samples 
(No.) 
Positive samples 
(No.) 
Positive 
samples  
(%) 
Farm A (unvaccinated) 39 31 8 20.5 
Farm B (vaccinated) 
which 
53 10 43 81.1 
55 days post vaccination 17 1 16 94.1 
70 days post vaccination 18 5 13 72.2 
85 days post vaccination 18 4 14 77.7 
 
In farm A, where the pigs were unvaccinated, after examining the 39 sera by using 
ELISA test it was highlighted the PCV-2 infection based on seroconversion. Of the 39 
examinated sera, 8 were positive, denoting a rate of seroconversion of 20.5%, associated with 
the presence of clinical signs and skin lesions (fig. 1). 
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Fig. 1 Skin lesions in infected pigs 
 
In farm B, where the pigs were vaccinated using IngelvacCircoFlex (Boehringer 
Ingelheim) 43 out of  53 examinated sera were positive, representing a percentage of 81.1. At 
55 days postvaccination, almost all pigs developed a postvaccination active immune response, 
so that 94.1% of sera were positive. At 70 days postvaccination 13 sera (72.2%) out of 18 were 
positive and at 85 days postvaccination 14 sera (77.7%) out of 18 were positive (fig. 2). 
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Fig. 2 The dynamic of positive samples, from vaccinated pigs against circovirosis 
 
The vaccine produces a good humoral immune response, so that immediately after 
vaccination almost all immunized pigs presented protective antibodies. The protection 
decreases slowly in time, so in at least 3 months postimmunization, 77.7% of pigs still 
presented active immunity proved by the ELISA kit used. 
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CONCLUSIONS 
 
• By using PCV-2 SERELISA ® Ab Mono Blocking (Synbiotics Europe, Lyon, France) test 
kit there were quantified PCV-2 antibodies in sera from infected or vaccinated pigs.  
• The percentage of seroconversion in infected pigs was 20.5% and this was associated with 
the presence of clinical signs and skin lesions.  
• In vaccinated pigs seroconversion was 94.1% at 55 days after vaccination and it decreased 
slowly in time, reaching 77.7% at 85 days postvaccination. 
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